Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25235633 | 0.83 | PLAAT3 (0.40) | SMN1; SMN2HPGDALDH1A1FFAR1RAB9A | |
| SCHEMBL23796021 | 0.81 | SORD (0.40) | POLBNPSR1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL445560 | 0.77 | STK17B (0.48) | POLBKDM4EGAA | |
| SCHEMBL23795904 | 0.77 | NPSR1 (0.38) | POLBNPSR1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL27850220 | 0.77 | FFAR1 (0.42) | FFAR1KDM4EGAA | |
| SCHEMBL21437557 | 0.76 | RAB9A (0.48) | POLBSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL17621392 | 0.76 | TRPV3 (0.33) | — | |
| SCHEMBL23796016 | 0.76 | CTSK (0.44) | POLBNPSR1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL23795894 | 0.76 | NPSR1 (0.37) | POLBNPSR1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL15578010 | 0.74 | NPSR1 (0.53) | POLBNPSR1SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | disclosed |
| US-10550099-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3194383-B1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190263779-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | disclosed |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3414233-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-12-19 | — | — | EP | disclosed |
| US-20180334451-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| US-10071988-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-11 | — | — | US | disclosed |
| US-20180134682-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
| EP-3194383-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044781-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| CN-101541764-B | Pyrimidylmethyl-sulfonamide compounds useful as fungicides and against arthropods | BASF SE | 2012-10-10 | — | — | CN | disclosed |
| CN-101541764-A | Pyrimidylmethyl-sulfonamide compounds useful as fungicides and against arthropods | BASF SE (DE) | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | POLB 1472/4885NPSR1 4487/4885SMN1; SMN2 3367/4885 |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | POLB 100/4885NPSR1 4473/4885SMN1; SMN2 2149/4885 |
| US-20180334451-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | POLB 3574/4885NPSR1 66/4885SMN1; SMN2 907/4885 |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | POLB 201/4885NPSR1 4826/4885SMN1; SMN2 3797/4885 |
| US-10550099-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | POLB 100/4885NPSR1 4473/4885SMN1; SMN2 2149/4885 |
| US-20180134682-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | POLB 100/4885NPSR1 4473/4885SMN1; SMN2 2149/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | POLB 1472/4885NPSR1 4487/4885SMN1; SMN2 3367/4885 |
| US-20190263779-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | POLB 100/4885NPSR1 4473/4885SMN1; SMN2 2149/4885 |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | POLB 3574/4885NPSR1 66/4885SMN1; SMN2 907/4885 |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | POLB 3574/4885NPSR1 66/4885SMN1; SMN2 907/4885 |
| US-10071988-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | POLB 3574/4885NPSR1 66/4885SMN1; SMN2 907/4885 |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | POLB 3574/4885NPSR1 66/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.